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Abstract
Zinc metabolism may regulate thyroid function acting at TRH (thyrotropin-releasing hormone)
synthesis, peripheral deiodination of T4 (tetraiodothyronine), and binding of thyroid hormones to
nuclear receptors. The aim of this study was to investigate the effect of acute zinc administration on
TSH (thyroid-stimulating hormone), FT3 (free triiodothyronine), and FT4 (free tetraiodothyronine) in
10 healthy individuals and 12 hyperthyroid patients with Graves’ disease. All these individuals were
studied following 25 mg Zn administered intravenously, at 7:00 a.m. after 12 h fast. Blood
samples collected at 0, 3, 30, 60, 90, and 120 min after zinc administration showed no significant
alteration in the plasma levels of TSH, FT3, and FT4 in hyperthyroid patients. There were no
changes in the plasma levels of FT3 and FT4 in the control subjects, but TSH levels were acutely
depressed by zinc administration. This study suggests that zinc given acutely and in
pharmacological doses does not affect thyroid function in hyperthyroid subjects, but affect plasma
TSH levels in healthy individuals.
Introduction
Graves’ disease is the most common form of thyrotoxicosis. It occurs at any age and is more
frequent in females. It is currently viewed as an autoimmune disease of unknown cause. The
pathogenesis is related to T iymphocytes that become sensitized to antigens within the thyroid
gland and stimulate B lymphocytes to synthesize antibodies to these antigens. TSHRAb (antibody
against the thyroid-stimulating hormone receptor) is one such antibody that acts in the thyroid cell
membrane and has the capacity to stimulate the thyroid cell to increase growth and function [1].
Thus, Graves’ disease consists of one or more of the following features: thyrotoxicosis, goiter,
exophthalmos, and pretibial myxedema [1].
Zinc is a metal that affects thyroid hormone function at several levels. For example, zinc deficiency
inhibits TRH synthesis [2,3] and depresses plasma TSH, T4, T3 (triiodothyronine) [2,3]. It is necessary
for extrathyroidal T4 to T3 conversion [,4], and it plays a role in T3 binding to nuclear receptor as
well as the binding of the receptor to DNA Is].
On the other hand, the interaction between thyroid hormone and zinc metabolism has also been
reported, but the data on these topics are still limited [,7,a]. Thus, hypo- or hyperthyroidism can
affect the absorption, transport, secretion and excretion of znc [9,10]. Moreover, chronic zinc
administration has been found to affect the circulating levels of TSH, T3, T4, and rT3 (reverse
triiodothyronine) [11]. There appears to be a close relationship between zinc and thyroid hormones,
but the interactive mechanism is unknown. A few studies have been reported on thyroid
metabolism in patients with thyroid diseases and associated zinc deficiency Is], but no previous
reports are available on thyroid status following acute zinc administration in patients with Graves’
disease.
In this study, we determined whether a single venous dose of zinc changes the plasma TSH, FT3,
and FT4 in healthy individuals and in hyperthyroid patients.
Material and methods
Subjects
The study group was comprised of 10 healthy individuals (5 of each sex, aged 24.10 + 1.96) and
12 hyperthyroid patients with Graves’ disease (1 male and 11 females, aged 27.25 _+ 7.31).
Healthy individuals (medical students or staff members) were free from endocrine disease, and
none used any type of medication. Clinical evidence and biochemical determination of TSH, FT3,
and FT4 confirmed the thyroid status of hyperthyroidism. Hyperthyroid patients received no
antithyroid drugs or beta-adrenergic blocker before this study, and they did not have other
endocrine complications. Duration of hyperthyroidism was recent (no longer than 3 mo). None of
the subjects were on a special diet, and were taking any form of vitamin or mineral supplements.
The protocol, which was approved by the Medical Ethics Committee, was explained to the patients
and written consent was obtained from all participants.
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Experimental design
Group 1 (control): Ten healthy individuals.
Group 2 (experimental): Twelve hyperthyroid patients.
Venous zinc tolerance test
This test was started at 7:00 a.m. after 12 h fast, with the subjects maintaining dorsal decubitus
throughout the test. Catheters for infusion were implanted into the antecubital veins of both
forearms and maintained with physiological saline. Basal blood samples were collected at-30 and
0 min for zinc, TSH, FT3, and FT4. Intravenous administration of 25 mg Zn++ (2 mL zinc sulfate)
over a period of 1 min was started at time 0 min (8:00 h). This dose was used because although it
is in the supraphysiological range, it is devoid of any toxic effects [12]. Blood samples were then
immediately collected from another vein in the contralateral arm at 3, 30, 60, 90, and 120 min.
Sample collection and analysis
Venipuncture was performed using plastic syringes without a tourniquet. Materials used for zinc
collection, separation, and storage are made of propylene plastic and metal free. Serum and
plasma samples were frozen and stored at -20 C until the time of measurement. We determined
zinc concentration in serum, not in plasma, to avoid the use of anticoagulants that are commonly a
source of zinc contamination. It was measured by atomic absorption spectrophotometer
(Shimadzu, AA680G, Japan) according to the instructions of manufacturers. Hemolyzed samples
were discarded. The intraassay error was 2.4% and sensitivity was 0.02 pg/mL. Plasma TSH, FT3,
and FT4 were measured by radioimmunoassay (Diagnostic Products Corporation, USA), with an
intraassay error of 3.8, 4.7, and 1.4%, and a sensitivity of 0.05 plU/mL, 0.02 pg/mL, and 0.1 pg/mL,
respectively.
Statistical analysis
Student’s test, linear regression test, and correlation analysis were used for statistical
assessments. All comparisons are considered to be statistically significant at the 5% significant
level (p<0.05).
Results
Zinc dose, body surface area (BSA) and body mass index (BMI)
We corrected the dose 25 mg Zn** by the BSA and found no significant difference between the
means of Groups 1 and 2, p>0.05 (Table I). Both the means BSA and BMI are not significantly
different between Groups and 2, p>0.05 (Table I).
Table I: Values of zinc dose (25 mg elemental zinc corrected to BSA of each control and hyperthyroid patient),
AUC (obtained from Table II and_ determined by the trapezoid rule), BSA (obtained from 1.73/mZ), and BMI
(obtained from weight (kg)/height (m)). These parameters were obtained from 10 healthy individuals and 12
hyperthl/roid patients with Graves’ disease.
GROUP GROUP 2
(Control) (Experimental)
ZINC DOSE (mg Zn/*/m2) 22.86 :t: 2.58 21.70 + 2.12
"p value p>0.05
AUC (mL.min1) 527.23:1:70.12 471.59 + 70.34
bp value p>0.05
BSA (m2)
Cp value
1.11 + 0.12 1.16 + 0.12
p>0.05
BMI (kg/m) 19.41:1:2.91 18.89 + 3.70
p value p>0.05
The values are represented as mean :t: SD for 10 healthy individuals in Group and 12 hyperthyroid patients in Group 2.
o.....,d Indicate no significant difference (p>0.05) between Group and Group2 by unpaired test.
Serum zinc (SZn*/) concentration
Basal serum zinc levels were in the normal range (0.7-1.2 pg/mL) and not different in controls (1.04
+ 0.22 pg/mL) and hyperthyroid patients (0.96 + 0.19 pg/mL), p>0.05 (Table II). During the venous
zinc tolerance test, SZn levels showed the same profile in the two groups (Figure 1A and Table
II), and there are no significant difference, by unpaired test, between the area under the curve
(AUC) from Group and Group 2, p>0.05 (Table I).
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Table I1: Values of Zinc, TSH, FT3, and FT4 during a single venous dose of 25 mg of elemental zinc
in 10 control individuals and 12 hyperth,roid patients.
TIME GROUP GROUP 2
(iin), IControl) IExperimental)
ZINC (pg/mL) 0 1.04 + 0.22 0.96 + 0.19
3 9.57 ::1:2.28 8.03 + 1.10
30 5.84 + 0.80 5.52 + 0.97
60 4.99 + 0.67 4.33 + 0.77
90 4.31 + 0.65 3.77 + 0.59
120 3.82 + 0.57 3.23 + 0.69
ap value *p>0.05
TSH (IIU/mL) 0 2.11 + 1.06 0.07 + 0.04
3 2.03 + 0.87 0.10 ::1:: 0.19
30 1.69 + 0.74 0.06 + 0.02
60 1.58 + 0.63 0.11 + 0.10
90 1.52 + 0.65 0.14 + 0.18
120 1.37 + 0.62 0.06 ::1:0.03
bp value **p<0.0001
FT3 (pg/mL) 0 2.46 -i- 0.80 28.85 + 9.52
3 2.53 + 0.71 29.34 + 9.19
30 2.30 + 0.51 31.46 + 10.63
60 2.31 -I- 0.32 29.72 + 9.81
90 2.42 :t: 0.32 30.00 + 10.59
120 2.45 + 0.64 29.96 + 12.58
p value **p<0.0001
FT4 (pg/mL) 0 12.39 :t: 3.09 98.67 + 36.10
3 12.01:1:2.10 96.46 + 31.06
30 12.25 :!: 2.50 98.62 + 27.69
60 12.50:1:2.49 103.17 + 9.76
90 13.91 + 4.15 102.34 + 7.94
120 12.85:1:3.18 100.59 + 5.60
value <0.0001
The values are represented as mean + SD.
Indicates no significant difference (p>0.05) between Group and Group 2 by unpaired test.
b,c,o,d Indicate a significant difference (p<0.0001) between Group and Group 2 by unpaired test.
Plasma TSH, FT3, and FT4 concentrations
The plasma TSH profile was depressed in hyperthyroid group than in control group. Plasma TSH
levels remained unaltered during acute venous zinc administration in the hyperthyroid group
(Figure 1B). In contrast, plasma TSH decreased significantly in the control group (Figure 1B), and
there was a significant correlation between serum zinc and TSH after zinc administration, r=
0.9850, p<0.001 (Figure 1A and 1B; Table II). Venous zinc administration did not change the
already elevated plasma levels of FT3 and FT4 in hyperthyroid group, as well as in control group
(Figure 1C and 1D)o
Discussion
Alteration in thyroid function has been reported in zinc deficient status [13,14], and thyroid hormones
have been shown to influence zinc metabolism at several levels, including absorption, transport,
distribution, and secretion [r,9,1s,lB]. In this respect, zinc-deficient rats presented low serum TSH, T3,
and T4 when compared to the ad libitum controls [2,3]. On the other hand, hypothyroidism induced
[9101 zinc deficiency in humans as well as zinc deficiency causes hypothyroidism [1]. The exact role
of zinc in regulating thyroid hormone metabolism is not known. In our experiment, we administered
intravenously a mean of 22.86 mg Zn*//m2 to healthy individuals and 21.70 mg Zn**/m= to
hyperthyroid patients (Table I) to observe the zinc effects on the plasma levels of TSH, FT3, and
FT4. The low plasma levels of TSH and high plasma levels of FT3 and FT4 were expected in the
hyperthyroid patients []. Because of that the statistical analysis showed significant differences
among TSH, FT3, and FT4 when comparing control individuals versus hyperthyroid patients,
p<0.0001 (Figure 1B, 1C, and 1D; Table II).
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Figure 1. Levels of zinc, TSH, FT3 and FT4 in normal individuals and 12 patients with Graves’ disease during
venous zinc tolerance test (25 mg Zn/*). The results are represented as mean + SD. (A) Values of serum zinc.
These two curves are not significantly different (p>0.05). (B) Values of plasma TSH. The two curves showing
TSH levels are significantly different (p <0.0001). In hyperthyroid patients, TSH levels are virtually not
detectable, whereas in control individuals, TSH levels decreased after zinc administration. (C) Values of
plasma FT3. These two curves are significantly different (p <0.0001). Acute zinc administration did not change
the plasma FT3 profile in both control and hyperthyroid groups. (D) Values of plasma FT4. Both plasma FT4
profiles are significantly different (p <0.0001), and again, not modified by acute zinc injection. All results are
mean + SD. (A): p >0.05 vs. control by linear regression and unpaired test, and (B), (C) and (D): p <0.0001
vs. control by unpaired test.
However, acute zinc administration did not modify the plasma TSH, FT3, and FT4 profiles in the
hyperthyroid group, but decreased the plasma TSH profile in the control group (Figure 1B, 1C, and
1D). This phenomenon could not be attributed to the circadian rhythm, since correlation analysis
revealed the existence of a strong positive correlation between zinc and TSH (r= 0.9850, p<0.001).
The levels of FT3 and FT4 remained unalterable because the fall in plasma TSH probably cannot
affect the free fractions of these hormones in 120 min [1]. Moreover, zinc did not significantly
change the plasma TSH levels in hyperthyroid patients because of the extremely low levels of this
hormone (0.08 + 0.03 plU/mL) during the test period. This is the first time that an experiment like
that was performed in humans (healthy and hyperthyroid individuals)injecting pharmacological
doses of zinc. In this regard, only zinc supplementation was realized in experimental animals. For
example, this metal decreased hepatic 5’-deiodinase activity and significantly reduced serum T4
levels in obese and lean mice [11]. Some sites of regulation of thyroid hormones by zinc have been
[4 13] [518l proposed, including peripheral deiodination of T4 binding of T3 to nuclear receptors
synthesis of TRH [2,4], and cell membrane stabilization [19]. However, we only observed the acute
zinc-induced decrement of plasma TSH levels in healthy individuals.
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In conclusion, this study indicated that zinc administered acutely and in pharmacological doses
does not alter the plasma levels of TSH, FT3, and FT4 in Graves’ disease patients, but decreases
TSH levels in healthy individuals.
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